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Introduction
Tumor angiogenesis is now widely accepted as one of the driving forces of tumor progression, invasion and metastasis. A comprehensive understanding of the underlying mechanisms that promote tumor angiogenesis is critically meaningful for more efficient and effective approaches targeting tumors.
SRC-1 has been reported to contribute to tumor progression and metastasis in both orthotopic as well as transgenic tumor models via promotion of cell proliferation, migration and invasion, induction of apoptotic resistance and endocrine resistance as well as promotion of tumor-stroma interplay (Dasgupta et al. 2014; Wang et al. 2016 ). In addition, multiple studies have demonstrated that circulating SRC-1 is likely to be a prognostic indicator in various malignancies, including breast cancer and prostate cancer (Walsh et al. 2014; Xu et al. 2014b ).
Steroid receptor coactivator 1 (SRC-1) belongs to the SRC/p160 family, which also includes SRC-2 and SRC-3 (Walsh et al. 2012) . SRC-1 functions as a transcriptional coactivator for steroid receptors, such as estrogen receptor (Tai et al. 2000) and androgen receptor (Agoulnik et al. 2005; Gregory et al. 2001) , as well as other transcriptional factors, such as polyomavirus enhancer activator 3 (PEA3) (Qin et al. 2009 ), Ets-2 (Al-azawi et al. 2008) , and AP-1 (Qin et al. 2011) . SRC-1 has been shown to play a role in the progression of prostate cancer and breast cancer. In androgen-dependent prostate tumors, increased SRC-1 expression correlates with lymph node metastasis (Agoulnik et al. 2005) . Ablation of SRC-1 in androgen-dependent prostate cancer cells represses the activation of androgen receptor target genes and decreases androgen receptor-dependent cellular proliferation (Agoulnik et al. 2005) . SRC-1 expression is significantly associated with high grade tumors, HER2 positivity, recurrence and resistance to endocrine therapy in breast cancer Xu et al. 2009 ). SRC-1 expression also serves as an independent predictor of disease-free survival in cancer patients (Hudelist et al. 2003; Myers et al. 2005) . SRC-1 has been shown to promote breast cancer cell proliferation by enhancing the function of estrogen receptor-α (Karmakar et al. 2009 ).
In this study, we revealed that SRC-1 is elevated in glioma vessels compared to non-tumor vessels.
In addition, tumor cell-associated SRC-1 facilitated tumor angiogenesis by up-regulating the expression of pro-angiogenic factors in tumor micrenvironment through the activation of PEA3-dependent D r a f t transcription. To the best of our knowledge, it is the first study concerning the contribution of SRC-1 to tumor angiogenesis in glioma.
Materials and methods

Cell culture and reagents
U87MG glioma cell, human umbilical vein endothelial cell (HUVEC) and mouse islet endothelial cell (MILE) were from Shanghai Life Academy of Sciences Cell Library (Shanghai, China). U87MG is a commonly studied glioma cell line. HUVEC is a common human EC type. MILE cells were isolated from C57BL/6 mouse pancreatic islet endothelial cells, as normal mouse EC model (Niederman et al. 2002) . Glioma cells were maintained in DMEM/F12 medium (Gibco, Carlsbad, CA, USA) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (Hyclone, Logan, UT, USA). Endothelial cells were cultured in RPMI-1640 medium (Gibco) with 10% fetal bovine serum. All cells were cultured in a humidified incubator with 5% CO 2 atmosphere at 37°C.
Tumor conditioned medium was collected from the indicated human glioma cells grown in 10-cm Petri dishes. Tumor conditioned medium was prepared from the glioma cell culture grown to near confluency.
After washing the incubator twice with serum free medium, cells were incubated in serum free EBM-2 medium in a humidified incubator for 24 hours. The supernatant was harvested, centrifuged at 2000× g at 4 °C for 10 minutes and supplemented with 5% FBS, 1% penicillin-streptomycin, 1% chemically Brain tissue specimens were frozen-sectioned. Sections for microdissection were stained with a fluorescent dye-tagged lectin, Ulex europaeus lectin I (UEA-I) (Vector Laboratories, Burlington, ON, Canada). Laser capture microdissection (LCM) was used to collect enriched brain endothelium RNA and protein as previously described (Murugesan et al. 2011) . Briefly, brain vessels were stained with a fluorescent dye-tagged lectin, Ulex europaeus lectin I (UEA-I) (Vector Laboratories, Burlington, ON, Canada) (1:20 dilution). The sections were rapidly washed in a phosphate buffer (0.2M phosphate buffer in DEPC-treated water, pH 7.3) and then dehydrated by sequential exposures to increasing concentrations of ethanol (70% ethanol 30s, 96% ethanol 30s, and 100% ethanol 30s), followed by incubation in xylene for 5 min. The slides were air-dried and the fluorescent dye-labeled vessels were observed under the microscope. LCM was performed using the ArcturusXT™ Microdissection One day before transfection, 5 × 10 4 cells per well (reaching about 30% confluency at the time of transfection) were cultured in six-well plates. These lentivirus were introduced into glioma cells treated with 8 ug/ml polybrene (Genechem) and complete medium. Transfection effects were observed by a fluorescence microscope after 48 h. Puromycin was used to purify these infected cells. Effective knockdown or forced expression was monitored by western blot analysis.
Quantitative real-time PCR
Total RNA in cells and tissues were extracted using RNAiso Plus (TaKaRa, Dalian, China). The concentrations of these RNA samples were then measured using a spectrophotometer and the RNA specimens were reverse-transcribed into cDNA using the Primescript RT reagent Kit (TaKaRa). The primer sequence and product size for human SRC-1 was: forward 5ʹ-ACC TCA TGG GTT GCC TCT TC -3ʹ and reverse 5ʹ-TGG GCT TTG GCA ATT TCT GC -3ʹ, 70 bp, for mouse SRC-1: forward 5ʹ-
The tissues and cells were lysed by RIPA Lysis Buffer (Beyotime Institute of Biotechnology, Beijing, China) containing PMSF and phosphatase inhibitor. An equal amount of each protein sample was separated by 8-12% SDS-PAGE and transferred onto PVDF membranes. After incubation with primary antibodies overnight at 4°C, the PVDF membranes were washed 3 times with TBST buffer, and incubated with secondary antibody for 1h at 37°C. Then the membranes were washed 3 times in TBST buffer and the amount of protein in each band was quantified using the Quantity One 4.6 computer software (Bio-Rad, Hercules, CA, USA).
Tube formation assay
HUVECs were plated in Matrigel (BD biosciences, Billerica, MA) precoated 48-well plate at 2 × 10 3 cells/well with conditioned medium from control, NC, SRC-1, Sh-NC or Sh-SRC-1 glioma cells.
Images were captured under bright-fields using a microscope (DM6000B; Leica, Wetzlar, Germany).
The tubule crosses were quantified by Image J software at three random 10×fields to get the sum. The experiment was repeated three times.
Corneal pocket angiogenesis assay
Animal studies were approved by the Institutional Review Board at Second Affiliated Hospital of Xi'an Jiao Tong University. For the mouse corneal pocket assay hydron pellets containing sucrose octasulfate and either a low dose of human bFGF (30 ng) plus human recombinant SRC-1 (80ng) or bFGF (30 ng) alone were implanted into corneal micropockets of 8-wk old male SD rats (Animal center of Xi'an Jiao Tong University, Xi'an, China). On day 7, angiogenesis in each eye was evaluated using a slit-lamp microscope and photographed. The area of neovascularization for each cornea was calculated from the length of the vessels (VL) invading the cornea as well as the clock hours (CH) covered with the formula VL × CH × 0.0628.
ELISA for VEGF and MMP-9 in cell culture supernatants
VEGF and MMP-9 concentration in supernatants of the cultured glioma cells was determined using commercial human VEGF ELISA kit (Cat.DVE00) and human MMP-9 ELISA kit (Cat.DMP900) according to the manufacturer's instructions (R&D System, Minneapolis, MN, USA).
Dual-luciferase reporter assays
The potential VEGF promoter (-2361 to +298) and MMP-9 promoter (-859 to +141) were amplified by PCR from the human genomic DNA and subcloned into pGL3-Basic (Promega, Madison, WI, USA) by Biogot Co. Ltd. (Nanjing, China). The primers are as follows: VEGF forward 5′-CCA TGG ATC CCG GGC AGC AGC CGC-3′ and reverse 5′-TAT AAC CAT GTA AGA AAG CTT TCT T-3′; MMP-9 forward 5′-CGG GGT ACC TGC TAC TGT CCC CTT TAC TG-3′and reverse 5′-CCC AGA TCT GTG AGG GCA GAG GTG TCT-3′. 5×PEA3 RE-Luc plasmid (5×PEA3/ETS binding sites) was constructed by Biogot following previously described (Bojovic and Hassell 2001) . The sequence of plasmid was confirmed by DNA sequencing.
For gene reporter assay, a mixture containing 0.5 μg of reporter plasmid and 10 ng of pRL-TK was co-transfected with 0.5-2μg expression plasmids into 293T cells by using X-treme GENE 9 DNA Transfection Reagent, as recommended by the manufacturer (Roche Diagnostics, Indianapolis, IN, USA). Luciferase activity was measured with Dual Luciferase Kit (Promega) and normalized to the internal transfection control provided by Renilla luciferase.
Immunoprecipitation
U87MG cells were cultured in 10-cm dishes (Corning, New York, NY) and treated with indicated reagents (VEGF 20ng/ml or GS4012 10μg/ml for 12 hours). Then cells were lysed in cell lysis buffer (1% Triton X-100, 150 mmol/L NaCl, 10 mmol/L Tris, pH 7.4, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.2 mmol/L Na 3 VO 4 , 0.5% NP-40, and complete protein cocktail inhibitors from Roche (Foster City, CA) on ice. Lysate (0.5mg) was precleared by incubation with Protein A/G plus-agarose (Santa Cruz Biotechnology, Dallas, TX) at 4°C with gentle shaking for 1h. The bead-nonspecific binding protein complexes were discarded by pulsing centrifugation at 12,000×g for 10 seconds. The precleared cell lysate was incubated with specific antibody (2μg) at 4°C with gentle shaking overnight. The agarose beads were collected by centrifugation, followed by being washed three times with cell lysis buffer, and the beads were extracted with western blot sample buffer and subjected to western blot assay as described above.
ChIP assay
ChIP assay was carried out using the EZ-ChIP™ kit (Upstate, Millipore Corporation, Billerica, D r a f t MA). Immunoprecipitation was carried out with anti-PEA3 antibody (Novus Biologicals) or isotype control IgG (1μg/ml; Millipore). PCR reactions generate productions from the promoter region of VEGF or MMP-9 gene. The promoter-specific primers of VEGF are as below: 5'-GAG GAA TCA AGC CAC TCA GAA T-3' (Forward) and 5'-GTC TTC GGT AGG CAC TGA ACT T-3' (Reverse). The primers of MMP-9: 5'-TGC GGA CTT ACA ACC TAC AGT G-3' (Forward) and 5'-TCT TTG ACT CAG CTT CCT CTC C-3' (Reverse).
Statistical analysis
Statistical analyses were performed using SPSS 17.0. Statistical differences among groups were analyzed by t-test or χ 2 -square test. P < 0.05 was considered to be statistically significant. All data are presented as mean ± standard deviation (SD).
Results
SRC-1 expression is upregulated in the tumor endothelium
To elucidate the expression of SRC-1 in tumor endothelium, human glioma microvessels were obtained from glioma specimens, while normal microvessels from non-tumor brain specimens used as control. The protein expression level of SRC-1 was higher in the glioma microvessels compared with non-tumor group (Fig. 1A) . QRT-PCR analysis also detected mRNA expression of SRC-1 in the glioma microvessels was significantly increased compared with normal (Fig. 1B) . In line with these findings, tumor ECs isolated from TRAMP tumor model exhibited significantly increased mRNA as well as protein expressions of SRC-1 in comparison with normal mouse islet endothelial cells (MILE, Fig.   1C&D ). The TRAMP model, a transgenic murine model for studying clinical prostate cancer progression, is also considered a good model for researches on tumor angiogenesis (Mishel et al. 2017; Raina et al. 2008; Reed et al. 2007 ). These findings implicated an upregulation of SRC-1 in tumorassociated endothelium, which further suggested that SRC-1 expression in cancer cells might promote angiogenesis.
SRC-1 induces migration and tube formation in endothelial cells
To explore the potential functional effect of SRC-1 in angiogenesis, SRC-1 was stably overexpressed or knocked down in ECs, followed by confirmation of altered SRC-1 expression by D r a f t western blot (Fig. 2A) . Consequently, migration rate of SRC-1-expressing HUVECs was significantly increased compared to control and NC-expressing groups, while it was inhibited in the two sh-SRC-1 (#1 and #2) transfected cells compared with sh-NC transfected cells (P<0.05, Fig. 2B&C) . Consistently, the tube-formation efficiency of SRC-1-expressing HUVECs was significantly elevated than control and NC-expressing groups, and sh-SRC-1 groups had decreased tube formation ability compared with control (P<0.05, Fig. 2D&E ). These above results suggested that SRC-1 could regulate critical functions of EC, including migration as well as tube-formation.
SRC-1 induces angiogenesis in vivo
To examine whether normal neovascularization was modulated by SRC-1 in vivo, the corneal pocket angiogenesis assay was performed by using recombinant human SRC-1. Slow release methylcellulose pellets containing recombinant human SRC-1 were surgically implanted into the corneal pocket of rat approximately 1 mm away from the limbus. We examined whether SRC-1 could facilitate an angiogenic factor-induced neovascular response. SRC-1 combined with low levels of bFGF (30 ng/pellet) produced a significantly higher angiogenic response in the cornea as compared to bFGF group (Fig. 2F) . Vessel length and total area of neovascularization were significantly enhanced in the SRC-1 treated cohort (Fig. 2G&H) . Hence, the above findings indicated that SRC-1 might facilitate growth factor initiated angiogenesis in vivo.
SRC-1 regulates angiogenesis via the expression of pro-angiogenic factors in glioma cells
To begin to elucidate the underlying mechanism by which SRC-1 in tumor cells might induce tumor angiogenesis or influence in vivo neovascularization in the cornea, we utilized qRT-PCR to detect the expression of pro-angiogenic regulators in U87MG glioma cell. The results showed that the expression of pro-angiogenic regulators including Prokineticin-2 (PROK2), Interleukin-6 (IL6), MCP-1 (CCL2), Angiopoietin-1 (ANGPT1) and Matrix metallopeptidase-14 (MMP-14) did not change obviously after modifying SRC-1 expression (Supplementary Fig. S2 ). However, the mRNA expression of VEGF was upregulated by 3-4-fold in SRC-1 expressing U87MG cells (P < 0.05, Fig. 3A ) and the protein level of VEGF was upregulated by 2-2.5-fold in SRC-1 expressing U87MG cells (P<0.05, Fig.   3C ). There was also a significantly elevated MMP-9 mRNA level in SRC-1 expressing glioma cells (P D r a f t < 0.05, Fig. 3B ), and the protein expression of MMP-9 was increased by 3-4-fold in SRC-1 expressing clones (P < 0.05, Fig. 3D ). Down-regulation of SRC-1 led to a 30-50% reduction in VEGF mRNA as well as 20-45% reduction in MMP-9 mRNA respectively (P<0.05, Fig. 3A&B ). Down-regulation of SRC-1 led to a 50-60% reduction in VEGF protein as well as 30-40% reduction in MMP-9 protein respectively (P<0.05, Fig. 3C&D ), which suggested that upregulated proangiogenic factors were derived by SRC-1 in glioma cells. Western blot analysis further indicated that VEGF and MMP-9 protein expression was upregulated in SRC-1 expressing cells and was down-regulated in sh-SRC-1 transfected glioma cells (Fig. 3E ).
Our next aim was to examine whether SRC-1 could stimulate the migration and tube formation of endothelial cells towards glioma. To study this, we used the transwell migration assay by plating endothelial cells in the upper chamber and conditioned medium from different transfected glioma cells was added to the lower chamber. Under these experimental conditions, we observed that SRC-1 overexpression in U87MG glioma cells resulted in higher migration and tube formation ability of endothelial cells ( Supplementary Fig. S3 B-E). In addition, the migration and tube formation were inhibited in the SRC-1 shRNA transfected group compared with sh-NC group ( Supplementary Fig. S3 B-E). Collectively, the above findings suggested that the expression of the pro-angiogenic factors might be specifically modulated by SRC-1 in glioma cells, which might induce tumor angiogenesis within tumor microenvironment.
SRC-1 stimulates pro-angiogenic factors expression in PEA3-dependent manner
Polyomavirus enhancer activator 3 (PEA3), a transcriptional activator, is currently considered to be involved in regulation of epithelial-mesenchymal transition (EMT), migration, invasion and chemotherapeutic resistance of cancer stem cells Gu et al. 2011; Qin et al. 2009 ). In order to assess whether the proangiogenic effect of SRC-1 was dependent on PEA3-mediated transcriptional activity, we used the luciferase reporter construct driven by a basal promoter and five reiterated ETS binding motifs. PEA3 is sufficient to enhance the activity of this reporter construct but this activity is substantially increased by co-expression of SRC-1 (P<0.05, Fig. 4A ). Furthermore, the promoter luciferase activity assay showed that SRC-1 expressing could stimulate the transcriptional D r a f t activity of VEGF and MMP-9 promoters in U87MG cell (P<0.05, Fig. 4B&C ). The knockdown of PEA3 led to suppression of VEGF and MMP-9 promoter transcriptional activity by SRC-1 expressing (P<0.05, Fig. 4B&C ). The upregulated expression of VEGF and MMP-9 in SRC-1 expressing U87MG cells was also suppressed by sh-PEA3 construct co-transfection (Fig. 4D&E) . Compared with sh-PEA3 transfected U87MG cells (Fig. 4D, decreased ~21 .6% v.s. U87MG/sh-NC group), the downregulation of VEGF protein was more significant in the U87MG cells co-transfected with sh-PEA3 and SRC-1 overexpressing constructs (decreased ~44.8% v.s. U87MG/sh-NC+SRC-1 group). The downregulation of MMP-9 was also more significant in the U87MG/sh-PEA3+SRC-1 group (Fig. 4D, decreased ~47.6% v.s. U87MG/sh-NC+SRC-1 group) than sh-PEA3 transfected U87MG cells (decreased ~29.0% v.s.
U87MG/sh-NC group). Supplementary Fig. S1A&B ). The expression of PEA3 in tumor ECs isolated from TRAMP model also did not change ( Supplementary Fig. S1C&D ). These results indicated that SRC-1 did not affect the expression of PEA3 protein in glioma.
Above results prompted us to test whether SRC-1 protein could interact with PEA3 protein under angiogenic stimulus. To test the possibility, U87MG cells were treated with VEGF and VEGF inducer GS4012 and the cell extracts were used to carry out immunoprecipitation assay. The results showed that SRC-1 interacted with PEA3 in the basal condition and co-immunoprecipitated SRC-1 protein with PEA3 protein was increased in VEGF or GS4012-treated glioma cells as compared with vehicle-treated cells (Fig. 4F&G) . In addition, knockdown of PEA3 restrained VEGF or GS4012 induced SRC-1 and PEA3 interaction (Fig. 4F&G) . ChIP assay provided additional evidence supporting a direct binding of PEA3 to VEGF and MMP-9 promoter within U87MG cells, through the identification of PCR products that were obtained under GS4012 treatment when specific antibody against PEA3 was used (Fig. 4H ).
Taken together, the above findings suggested that the proangiogenic effect of SRC-1 was likely to be mediated by PEA3 activation in tumor cells, which in turn constructed a positive angiogenic response.
Tumor-associated SRC-1 might activate the PEA3 signaling in the tumor-associated endothelium or D r a f t surrounding epithelium proximal to the tumor as well.
Discussion
In the current study, we demonstrated that SRC-1 protein and mRNA were upregulated in microvessels from glioma tissues. And SRC-1 expression was significantly increased in the ECs isolated from TRAMP tumor model. In addition, we found that cell migration and tube-formation was increased by the stable expression of SRC-1 in EC cell and that knockdown of SRC-1 suppressed EC migration and tube formation, which indicates that these EC properties are influenced by SRC-1. Furthermore, the results of the corneal micropocket assay suggested that recombinant SRC-1 promoted prominent angiogenesis in the presence of low levels of bFGF ( Fig. 2F-G) , indicating that SRC-1 facilitates growth-factor initiated angiogenesis. To the best of our knowledge, it is the first study to establish a correlation between elevated SRC-1 levels in tumor epithelium and a concomitant pro-angiogenic effect on tumor microenvironment.
Number of studies showed that steroid receptors were found to be deregulated in tumor and to regulate the biological behaviors of tumor (Mishra et al. 2009; Zhang et al. 2013) . The upregulation of SRC-1 has been detected in tumor-associated vasculature in ovarian (Kumagami et al. 2011) , breast (Xu et al. 2014a ) and hepatocellular cancers (Tong et al. 2015) . However, it remains unclarified whether SRC-1 promotes or contributes to tumor angiogenesis. SRC-1 is a transcriptional coactivator not only for steroid receptors, such as androgen receptor (Agoulnik et al. 2005; Gregory et al. 2001 ) and estrogen receptor (Tai et al. 2000) , but also for other transcription factors, including PEA3 (Qin et al. 2009 ), Ets-2 (Al-azawi et al. 2008 , and AP-1 (Qin et al. 2011) . Through these receptors and transcription factors, SRC-1 coactivates the expression of some inflammatory factors (IL-8), transcription factors (Twist), integrins (Integrin α-5), growth factors (VEGF), oncogenes (Myc) and matrix metalloproteinases (MMP-7, MMP-9, MMP-11), and therefore plays pivotal but differential roles in the cancer metastasis, including the EMT, microenvironment remodeling, local adhesion, migration, invasion and intravasation of cancer cells, local inflammatory events and angiogenesis [reviewed by Zhang et al. (Zhang et al. 2013)] . A very recent study demonstrated that SRC-2, another member of SRC/p160 family, coordinates cardiomyocyte secretion of VEGF to promote pressure overload-induced D r a f t angiogenesis, in response to hypertrophic and hypoxic pressure (Suh et al. 2017 ). In our study, overexpression of SRC-1 in U87MG cell led to significantly elevated pro-angiogenic factors, VEGF as well as MMP-9, and knock-down of SRC-1 inhibited VEGF and MMP-9 expression at mRNA and protein level (Fig. 3) . Therefore, elevated SRC-1 levels in tumors are likely to be associated with enhanced expression of pro-angiogenic factors. These outcomes indicate that SRC-1 in tumor endothelial cells is likely to potentiate a pro-angiogenic tumor microenvironment, subsequently leading to enhanced tumor growth as well as more aggressive metastasis.
Next, we examined the underlying mechanisms of the regulatory role of SRC-1 on these proangiogenic effects. The results showed that SRC-1 directly enhanced VEGF and MMP-9 expression by potentiating PEA3-mediated VEGF and MMP-9 mRNA transcription. Down-regulation of PEA3 diminished SRC-1 induced activation of VEGF and MMP-9 promoter (Fig. 4) . It was reported that SRC-1 stimulates Twist transcription by recruiting PEA3 to Twist promoter and potentiating PEA3-mediated promoter activation (Qin et al. 2009 ). Further results indicated that PEA3 directly binds with SRC-1 in glioma cell and their binding increased under VEGF or VEGF inducer GS4012 treatment (Fig. 4F&G) .
The results also showed that a direct binding of PEA3 on VEGF and MMP-9 promoter induced by GS4012 in U87MG cells (Fig. 4H) . PEA3 (also known as E1AF and ETV4) along with ETV1 and ETV5 are members of ETS-oncogene family transcription factor (Oh et al. 2012) . The overexpression of PEA3 is associated with advanced and more aggressive forms of the tumor with worse prognosis (Keld et al. 2011) . It was reported that PEA3 could be regulated by EGFR and could regulate the transcription of MMP-9 and MMP-14 through binding with their promoter (Cowden et al. 2007 ). Moreover, a role of PEA3 has also been established in anchorage-independent growth (Hollenhorst et al. 2011) , enhanced motility and invasiveness (Kherrouche et al. 2015) , epithelial to mesenchymal transition (Pellecchia et al. 2012) , and tumorigenesis (Jiang et al. 2007a; Pellecchia et al. 2012) . In oesophageal squamous cell carcinoma, PEA3 promotes tumorigenicity and metastasis through enhancing MMP-2 and MMP-9 activity (Fung et al. 2016) . It is worth noting that PEA3 functions a positive invasion regulator in glioma in cooperation with transcription factor SP1 via activating transcription of glioma-related gene for beta1,4-galactosyltransferase V (Jiang et al. 2007b) . The results in our study further yield the important D r a f t mechanistic insights into the role of PEA3 in glioma progression, and PEA3-focussed basic and translational studies in glioma need further investigation.
In summary, the present study revealed for the first time that SRC-1 was highly expressed in microvessels from glioma tissues. Expressing of SRC-1 induced EC migration and tube formation in vitro and induced angiogenesis in vivo. The regulating role of SRC-1 in tumor angiogenesis depended on the PEA3-mediated expression of pro-angiogenic factors. To the best of our knowledge, it is the first study to establish a correlation between elevated SRC-1 levels in tumor epithelium and a concomitant pro-angiogenic effect on tumor microenvironment. Based on these findings, SRC-1/PEA3 can be considered as a potential target in the therapy for glioma in the future. 
